Angioimmunoblastic T-cell lymphoma – Pipeline Insight, 2020
This report can be delivered to the clients within 48-72 Hours
DelveInsight’s, “Angioimmunoblastic T-cell lymphoma – Pipeline Insight, 2020,” report provides comprehensive insights about 10+ companies and 10+ pipeline drugs in Angioimmunoblastic T-cell lymphoma pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
Geography Covered
Angioimmunoblastic T-cell lymphoma: Overview
Angioimmunoblastic T-cell lymphoma (AITL) is a type of peripheral T-cell lymphoma arising from follicular helper T cells of the germinal center. AITL is characterized by the transformation of a T-cell into a malignant cell. It is a systemic disease that is present with generalized lymphadenopathy, hepatosplenomegaly, constitutional symptoms, skin rash, anemia, and polyclonal hypergammaglobulinemia. The Abnormal, uncontrolled growth and multiplication (proliferation) of malignant T-cells may lead to enlargement of a specific lymph node region or regions.
Symptoms
The symptoms of Angioimmunoblastic T-cell lymphoma include:
Diagnosis of Angioimmunoblastic T-cell lymphoma (AITL) is based upon identification of characteristic symptoms, a detailed patient history, a thorough clinical evaluation and a biopsy of an affected lymph node or other affected areas such as the skin or bone marrow. A series of other tests may be done to determine the extent, or stage, of the disease such as blood tests, specialized imaging tests and bone marrow examination. Specialized imaging techniques may include magnetic resonance imaging (MRI), computed tomography (CT) scanning, and positron emission tomography (PET scan).
Treatment
Treatment of Angioimmunoblastic T-cell lymphoma is based on the assessment of the extent or “stage” of the disease progression, tumor size, presence or absence of certain symptoms, an individual’s age and general health. It will help in characterizing the potential disease course and appropriate treatment approaches. A combination of chemotherapy and immunotherapy (chemoimmunotherapy) have been used. Corticosteroids, such as prednisone, are used to treat the symptoms of AITL that result from dysfunction of the immune system. Investigational therapies includes low dose methotexate with corticosteroids, thalidomide, lenalidomide, bevacizumab, alemtuzumab, fludarabine and 2-chlordeoxyadenosine. The use of interferon alfa in association with or following chemotherapy is also under evaluation.
Angioimmunoblastic T-cell lymphoma Emerging Drugs Chapters
This segment of the Angioimmunoblastic T-cell lymphoma report encloses its detailed analysis of various drugs in different stages of clinical development, including phase II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.
Angioimmunoblastic T-cell lymphoma Emerging Drugs
Further product details are provided in the report
Angioimmunoblastic T-cell lymphoma: Therapeutic Assessment
This segment of the report provides insights about the different Angioimmunoblastic T-cell lymphoma drugs segregated based on following parameters that define the scope of the report, such as:
Angioimmunoblastic T-cell lymphoma: Pipeline Development Activities
The report provides insights into different therapeutic candidates in phase II, I, preclinical and discovery stage. It also analyses Angioimmunoblastic T-cell lymphoma therapeutic drugs key players involved in developing key drugs.
Pipeline Development Activities
The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Angioimmunoblastic T-cell lymphoma drugs.
Report Highlights
Current Treatment Scenario and Emerging Therapies:
DelveInsight’s, “Angioimmunoblastic T-cell lymphoma – Pipeline Insight, 2020,” report provides comprehensive insights about 10+ companies and 10+ pipeline drugs in Angioimmunoblastic T-cell lymphoma pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
Geography Covered
- Global coverage
Angioimmunoblastic T-cell lymphoma: Overview
Angioimmunoblastic T-cell lymphoma (AITL) is a type of peripheral T-cell lymphoma arising from follicular helper T cells of the germinal center. AITL is characterized by the transformation of a T-cell into a malignant cell. It is a systemic disease that is present with generalized lymphadenopathy, hepatosplenomegaly, constitutional symptoms, skin rash, anemia, and polyclonal hypergammaglobulinemia. The Abnormal, uncontrolled growth and multiplication (proliferation) of malignant T-cells may lead to enlargement of a specific lymph node region or regions.
Symptoms
The symptoms of Angioimmunoblastic T-cell lymphoma include:
- high fever
- night sweats
- skin rash
- enlargement of a specific lymph node region or regions
- autoimmune disorders such as autoimmune hemolytic anemia and immune thrombocytopenia
Diagnosis of Angioimmunoblastic T-cell lymphoma (AITL) is based upon identification of characteristic symptoms, a detailed patient history, a thorough clinical evaluation and a biopsy of an affected lymph node or other affected areas such as the skin or bone marrow. A series of other tests may be done to determine the extent, or stage, of the disease such as blood tests, specialized imaging tests and bone marrow examination. Specialized imaging techniques may include magnetic resonance imaging (MRI), computed tomography (CT) scanning, and positron emission tomography (PET scan).
Treatment
Treatment of Angioimmunoblastic T-cell lymphoma is based on the assessment of the extent or “stage” of the disease progression, tumor size, presence or absence of certain symptoms, an individual’s age and general health. It will help in characterizing the potential disease course and appropriate treatment approaches. A combination of chemotherapy and immunotherapy (chemoimmunotherapy) have been used. Corticosteroids, such as prednisone, are used to treat the symptoms of AITL that result from dysfunction of the immune system. Investigational therapies includes low dose methotexate with corticosteroids, thalidomide, lenalidomide, bevacizumab, alemtuzumab, fludarabine and 2-chlordeoxyadenosine. The use of interferon alfa in association with or following chemotherapy is also under evaluation.
Angioimmunoblastic T-cell lymphoma Emerging Drugs Chapters
This segment of the Angioimmunoblastic T-cell lymphoma report encloses its detailed analysis of various drugs in different stages of clinical development, including phase II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.
Angioimmunoblastic T-cell lymphoma Emerging Drugs
- Tipifarnib: Kura Oncology
- AUTO4: Autolus
Further product details are provided in the report
Angioimmunoblastic T-cell lymphoma: Therapeutic Assessment
This segment of the report provides insights about the different Angioimmunoblastic T-cell lymphoma drugs segregated based on following parameters that define the scope of the report, such as:
- Major Players in Angioimmunoblastic T-cell lymphoma
- There are approx. 10+ key companies which are developing the therapies for Angioimmunoblastic T-cell lymphoma. The companies which have their Angioimmunoblastic T-cell lymphoma drug candidates in the most advanced stage, i.e. phase II include, Kura Oncology.
- Phases
- Mid-stage products (Phase II)
- Early-stage product (Phase I) along with the details of
- Pre-clinical and Discovery stage candidates
- Discontinued & Inactive candidates
- Route of Administration
- Oral
- Parenteral
- intravitreal
- Subretinal
- Topical.
- Molecule Type
- Monoclonal Antibody
- Peptides
- Polymer
- Small molecule
- Gene therapy
- Product Type
Angioimmunoblastic T-cell lymphoma: Pipeline Development Activities
The report provides insights into different therapeutic candidates in phase II, I, preclinical and discovery stage. It also analyses Angioimmunoblastic T-cell lymphoma therapeutic drugs key players involved in developing key drugs.
Pipeline Development Activities
The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Angioimmunoblastic T-cell lymphoma drugs.
Report Highlights
- The companies and academics are working to assess challenges and seek opportunities that could influence Angioimmunoblastic T-cell lymphoma R&D. The therapies under development are focused on novel approaches to treat/improve Angioimmunoblastic T-cell lymphoma.
- Angioimmunoblastic T-cell lymphoma Pipeline Analysis
- Therapeutic Assessment
- Unmet Needs
- Impact of Drugs
- Pipeline Product Profiles
- Therapeutic Assessment
- Pipeline Assessment
- Inactive drugs assessment
- Unmet Needs
Current Treatment Scenario and Emerging Therapies:
- How many companies are developing Angioimmunoblastic T-cell lymphoma drugs?
- How many Angioimmunoblastic T-cell lymphoma drugs are developed by each company?
- How many emerging drugs are in mid-stage, and late-stage of development for the treatment of Angioimmunoblastic T-cell lymphoma?
- What are the key collaborations (Industry–Industry, Industry–Academia), Mergers and acquisitions, licensing activities related to the Angioimmunoblastic T-cell lymphoma therapeutics?
- What are the recent trends, drug types and novel technologies developed to overcome the limitation of existing therapies?
- What are the clinical studies going on for Angioimmunoblastic T-cell lymphoma and their status?
- What are the key designations that have been granted to the emerging drugs?
- Kura Oncology
- Bristol-Myers Squibb
- Celgene
- Pfizer
- Autolus
- BeiGene
- Amgen
- CerRx
- PersonGen Biotherapeutics
- Takeda
- Celgene
- Arno Therapeutics
- Tipifarnib
- Dasatinib
- Enasidenib
- Azacitidine
- AUTO4
- Tislelizumab
- Carfilzomib
- Fenretinide intravenous
- CD7-CAR-T cells
- MLN8237
- Bortezomib
- Lenalidomide
- AR-42
Introduction
Executive Summary
Angioimmunoblastic T-cell lymphoma: Overview
Causes
Mechanism of Action
Signs and Symptoms
Diagnosis
Disease Management
Pipeline Therapeutics
Comparative Analysis
Therapeutic Assessment
Assessment by Product Type
Assessment by Stage and Product Type
Assessment by Route of Administration
Assessment by Stage and Route of Administration
Assessment by Molecule Type
Assessment by Stage and Molecule Type
Angioimmunoblastic T-cell lymphoma – DelveInsight’s Analytical Perspective
In-depth Commercial Assessment
Angioimmunoblastic T-cell lymphoma companies’ collaborations, Licensing, Acquisition -Deal Value Trends
Angioimmunoblastic T-cell lymphoma Collaboration Deals
Company-Company Collaborations (Licensing / Partnering) Analysis
Company-University Collaborations (Licensing / Partnering) Analysis
Mid Stage Products (Phase II)
Comparative Analysis
Tipifarnib: Kura Oncology
Product Description
Research and Development
Product Development Activities
Drug profiles in the detailed report
Early Stage Products (Phase I/II)
Comparative Analysis
Dasatinib: Bristol-Myers Squibb
Product Description
Research and Development
Product Development Activities
Drug profiles in the detailed report
Inactive Products
Comparative Analysis
Angioimmunoblastic T-cell lymphoma Key Companies
Angioimmunoblastic T-cell lymphoma Key Products
Angioimmunoblastic T-cell lymphoma- Unmet Needs
Angioimmunoblastic T-cell lymphoma- Market Drivers and Barriers
Angioimmunoblastic T-cell lymphoma- Future Perspectives and Conclusion
Angioimmunoblastic T-cell lymphoma Analyst Views
Angioimmunoblastic T-cell lymphoma Key Companies
Appendix
Executive Summary
Angioimmunoblastic T-cell lymphoma: Overview
Causes
Mechanism of Action
Signs and Symptoms
Diagnosis
Disease Management
Pipeline Therapeutics
Comparative Analysis
Therapeutic Assessment
Assessment by Product Type
Assessment by Stage and Product Type
Assessment by Route of Administration
Assessment by Stage and Route of Administration
Assessment by Molecule Type
Assessment by Stage and Molecule Type
Angioimmunoblastic T-cell lymphoma – DelveInsight’s Analytical Perspective
In-depth Commercial Assessment
Angioimmunoblastic T-cell lymphoma companies’ collaborations, Licensing, Acquisition -Deal Value Trends
Angioimmunoblastic T-cell lymphoma Collaboration Deals
Company-Company Collaborations (Licensing / Partnering) Analysis
Company-University Collaborations (Licensing / Partnering) Analysis
Mid Stage Products (Phase II)
Comparative Analysis
Tipifarnib: Kura Oncology
Product Description
Research and Development
Product Development Activities
Drug profiles in the detailed report
Early Stage Products (Phase I/II)
Comparative Analysis
Dasatinib: Bristol-Myers Squibb
Product Description
Research and Development
Product Development Activities
Drug profiles in the detailed report
Inactive Products
Comparative Analysis
Angioimmunoblastic T-cell lymphoma Key Companies
Angioimmunoblastic T-cell lymphoma Key Products
Angioimmunoblastic T-cell lymphoma- Unmet Needs
Angioimmunoblastic T-cell lymphoma- Market Drivers and Barriers
Angioimmunoblastic T-cell lymphoma- Future Perspectives and Conclusion
Angioimmunoblastic T-cell lymphoma Analyst Views
Angioimmunoblastic T-cell lymphoma Key Companies
Appendix
LIST OF TABLES
Table 1 Total Products for Angioimmunoblastic T-cell lymphoma
Table 2 Late Stage Products
Table 3 Mid Stage Products
Table 4 Early Stage Products
Table 5 Pre-clinical & Discovery Stage Products
Table 6 Assessment by Product Type
Table 7 Assessment by Stage and Product Type
Table 8 Assessment by Route of Administration
Table 9 Assessment by Stage and Route of Administration
Table 10 Assessment by Molecule Type
Table 11 Assessment by Stage and Molecule Type
Table 12 Inactive Products
Table 1 Total Products for Angioimmunoblastic T-cell lymphoma
Table 2 Late Stage Products
Table 3 Mid Stage Products
Table 4 Early Stage Products
Table 5 Pre-clinical & Discovery Stage Products
Table 6 Assessment by Product Type
Table 7 Assessment by Stage and Product Type
Table 8 Assessment by Route of Administration
Table 9 Assessment by Stage and Route of Administration
Table 10 Assessment by Molecule Type
Table 11 Assessment by Stage and Molecule Type
Table 12 Inactive Products
LIST OF FIGURES
Figure 1 Total Products for Angioimmunoblastic T-cell lymphoma
Figure 2 Late Stage Products
Figure 3 Mid Stage Products
Figure 4 Early Stage Products
Figure 5 Preclinical and Discovery Stage Products
Figure 6 Assessment by Product Type
Figure 7 Assessment by Stage and Product Type
Figure 8 Assessment by Route of Administration
Figure 9 Assessment by Stage and Route of Administration
Figure 10 Assessment by Molecule Type
Figure 11 Assessment by Stage and Molecule Type
Figure 12 Inactive Products
Figure 1 Total Products for Angioimmunoblastic T-cell lymphoma
Figure 2 Late Stage Products
Figure 3 Mid Stage Products
Figure 4 Early Stage Products
Figure 5 Preclinical and Discovery Stage Products
Figure 6 Assessment by Product Type
Figure 7 Assessment by Stage and Product Type
Figure 8 Assessment by Route of Administration
Figure 9 Assessment by Stage and Route of Administration
Figure 10 Assessment by Molecule Type
Figure 11 Assessment by Stage and Molecule Type
Figure 12 Inactive Products
